Nils Lonberg

Board member

Nils has 30 years of operational experience in Biotech and Pharma, focusing on platform innovation, drug discovery, and drug development. Most recently, he was Senior Vice President, Oncology Discovery Biology, at Bristol-Myers Squibb, where he led drug discovery efforts for both targeted and immuno-oncology agents, including the checkpoint blockade therapies ipilimumab and nivolumab. Nils also has experience in startup and midsize biotech, serving as Scientific Director at GenPharm and Medarex. He received his PhD in Biochemistry and Molecular Biology from Harvard University, and was elected to the National Academy of Engineering in 2015.